February 2026 Research Update

This month added a clearer signal that different enzyme treatments for late-onset Pompe disease can lead to different results for walking ability and breathing over about a year, but real-world follow-up still often looks more like stability than big change. Across analyses, cipaglucosidase alfa plus miglustat more often lined up with better combined walking and lung outcomes than alglucosidase alfa, while a broad review of many studies still found only modest average gains and uncertainty when comparing enzyme products. Taken together, the picture is that treatment benefits are real but vary widely from person to person, and long-term change may still be gradual even with therapy. [1] [2] [3] [4]

In adults who switched from alglucosidase alfa to cipaglucosidase alfa plus miglustat, a post hoc analysis reported a higher likelihood of clinically meaningful improvement in a combined measure of walking distance and breathing capacity compared with staying on alglucosidase alfa plus placebo. The same report also described fewer people worsening in those combined outcomes after switching. This helps explain why some patients and teams are interested in switching strategies, while also reminding us that not everyone improves on any single approach. [1]

A separate comparison that combined data across multiple trials also favored cipaglucosidase alfa plus miglustat over alglucosidase alfa at 52 weeks for both walking distance and percent-predicted breathing capacity. The analysis reported high certainty in the direction of the difference, including across groups with different prior exposure to enzyme therapy. This adds another piece of evidence pointing the same way, although it is still built from combining different study sources rather than a single head-to-head trial for every situation. [2]

A large evidence synthesis comparing enzyme replacement therapy (ERT) with best supportive care found that, on average, ERT-naive patients had modest short-term gains in the 6-minute walk test after about 1 year, while breathing changes were less clearly different. When comparing different ERT products, the review found limited evidence for large differences, and sensitivity analyses reduced confidence in apparent advantages. Over 10 to 15 years, single-group follow-up studies suggested early gains may be followed by gradual declines in walking and breathing measures, with substantial uncertainty because long-term comparisons are difficult. [3]

In routine care in Germany, adults who switched from alglucosidase alfa to either avalglucosidase alfa or cipaglucosidase alfa plus miglustat were reported to be broadly stable over follow-up of up to 24 months, with rare infusion-associated reactions. Some measures changed over time, but the study did not find clear switch-type effects, and missing data increased as follow-up continued. This kind of real-world study helps set expectations that day-to-day outcomes after a switch may look stable for many people, even when trials show average differences between therapies. [4]

One cross-sectional study focused on gastrointestinal symptoms and reported milder symptoms in people on standard-dose ERT compared with reduced-dose or no ERT, while longer time on ERT was linked to more constipation. The same report noted worse gastrointestinal symptom scores in people with factors like lower income, need for respiratory support, scoliosis, and tongue changes. Because this was a one-time snapshot, it cannot prove that dose caused the symptom differences, but it highlights that digestive symptoms are common and may track with overall disease burden and treatment patterns. [5]

For patients and caregivers, this month strengthens the idea that outcomes on enzyme therapy are not one-size-fits-all, and that some newer regimens may show better average walking and breathing results over about a year in clinical trial datasets. At the same time, longer-term evidence still points to gradual change for many people, and real-world switch studies often show stability rather than dramatic improvement. This information may matter most when discussing expectations and when researchers plan future studies, because it clarifies where differences between therapies look most likely and where uncertainty remains. What is still not clear from these reports is how well any group-level difference predicts what will happen for a specific individual, especially over many years. [1] [2] [3] [4] [5]

This month, several studies aimed to measure Pompe disease more precisely, either by improving how the diagnosis is found or by adding tools that may track disease activity and breathing muscle weakness. The overall pattern is early but practical progress: large-scale screening work clarified genetic findings in a real population, and smaller studies suggested new imaging and urine measures that could help follow the disease over time. None of these tools is presented as a finished answer yet, but together they move the field toward more consistent ways to detect Pompe disease and measure change. [6] [7] [8] [9]

A large diagnostic effort in Russia screened 15,068 people with suspected Pompe disease and identified many disease-causing GAA gene variants, including 25 described as novel. The work also highlighted a common late-onset variant (c.-32-13T>G) and showed how different testing pathways (enzyme activity testing plus targeted gene sequencing, or broader gene-panel testing with follow-up enzyme testing) can both detect Pompe disease. For families, this adds evidence that the genetic landscape can differ by region and that some genetic results, such as pseudodeficiency variants, need careful interpretation alongside enzyme testing. [6]

A 4-year follow-up study reported that higher baseline levels of a urine marker, glucose tetrasaccharide (Glc4), were linked to greater later decline in walking distance and to more muscle fat replacement on muscle imaging. The study also reported that baseline Glc4 predicted decline with moderate accuracy and remained an independent predictor of 6-minute walk decline in their analyses. For patients, this supports Glc4 as a candidate marker for tracking disease activity and future risk, although the report also noted substantial variability within individuals over time. [7]

In a small study comparing 11 adults with late-onset Pompe disease to 11 controls, real-time MRI measurements showed clear differences in how the diaphragm moved, including reduced motion and paradoxical movement during sniff in most patients. Measures of fatty or fibrous change in part of the diaphragm also differed and correlated with standard breathing tests and ultrasound findings. This suggests imaging might capture diaphragm weakness in a more direct way than routine tests alone, but the approach needs more validation and is not widely available yet. [8]

Another early imaging approach, glycoNOE MRI, distinguished Pompe mice from healthy mice and detected changes after enzyme therapy that matched lab glycogen measurements. In a very small human pilot, 2 Pompe patients showed higher muscle glycogen signal than healthy controls. This is promising as a way to measure muscle glycogen directly, but the human evidence is still extremely limited in size, so it mainly signals a research direction rather than a ready-to-use test. [9]

For patients, this theme is mainly about measurement: finding Pompe disease sooner and tracking it more clearly once diagnosed. The diagnostic screening study may matter now in settings considering how to structure testing and how to interpret genetic results that can look confusing without enzyme confirmation. The urine marker (Glc4) and the newer MRI approaches may matter later if confirmed, because they could help describe disease activity and diaphragm weakness in a more consistent way over time. What remains uncertain is how well these newer markers will predict day-to-day function for an individual, and which of them will become practical and standardized enough for broad use. [6] [7] [8] [9]

This month included work focused on how Pompe care may be delivered in new ways, especially as gene therapy moves closer to real-world use and as some infusions shift from clinic to home. The shared message is planning and safety: experts emphasized the need for specialized centers and long-term follow-up systems for gene therapy, and pooled trial data suggested home infusion of a specific enzyme regimen had infusion reaction rates similar to clinic infusion. Together, these reports focus less on changing disease outcomes and more on building safer, more organized pathways for complex treatments. [10] [11]

An expert-consensus roadmap described what a patient-centered center of excellence for Pompe gene therapy might include, from diagnosis and pre-therapy assessment to infusion-era monitoring and long-term follow-up. It highlighted the need for multidisciplinary teams, standardized procedures, infrastructure, data collection, and international collaboration, and it listed adverse events that should be watched for around gene therapy infusion. Because this is expert guidance rather than outcome data, it does not show how well gene therapy works, but it clarifies what systems experts think are needed to deliver it safely and consistently. [10]

A pooled safety analysis from three clinical trials reported similar rates of infusion-associated reactions when cipaglucosidase alfa plus miglustat was given at home versus in clinic. The report included 2 serious infusion reactions among people receiving home infusions and also described 2 medication errors with no adverse outcomes. For families, this provides structured safety information supporting the possibility of home infusion in selected adults, while also underscoring that monitoring and careful medication handling still matter in any setting. [11]

For patients and caregivers, these studies are about how care might be organized rather than which treatment is best. The gene therapy roadmap may matter in the near future by setting expectations for what evaluation, monitoring, and long-term follow-up could look like if gene therapy becomes more widely available. The home-infusion safety analysis may matter now for understanding what was observed in clinical trial settings for cipaglucosidase alfa plus miglustat, including that serious reactions were uncommon but did occur. What remains uncertain is how these delivery models will look across different health systems and how closely real-world experiences will match the controlled conditions and eligibility rules used in trials. [10] [11]

This month also included early-stage evidence that helps explain disease biology and explores intensive treatment approaches, but it is not the kind of evidence that can be generalized to most patients. A single infant case described strong early improvements on a high-frequency avalglucosidase alfa regimen with immune tolerance induction, while a mouse study provided a model for studying heart and muscle disease and testing future treatment ideas. The main value here is building understanding and generating ideas to test in larger human studies. [12] [13]

In one treatment-naive infant with classic infantile-onset Pompe disease, a case report described marked improvements in heart measures, motor development, and lab markers after 2 months of high-dose weekly avalglucosidase alfa along with immune tolerance induction, followed by stability through 18 months on a less frequent schedule. The report noted no adverse reactions and no detectable anti-drug antibodies in this child. This is encouraging for research discussions about early intensive therapy, but it remains a single-patient experience that may be strongly shaped by individual factors such as CRIM status and immunomodulation. [12]

A mouse model study tracked disease features over time and found early heart enlargement with declining heart function, reduced body mass, movement and strength problems, low GAA enzyme activity, and high glycogen in multiple tissues compared with healthy mice, while survival was unchanged. This type of work matters because it provides a consistent model for testing ideas about how Pompe affects different organs over time. It does not directly tell patients what will happen in humans, but it supports the biological link between low GAA activity and glycogen buildup across tissues. [13]

For families, these reports are mainly signals that guide future research rather than answers that can be applied broadly today. The infant case shows what was possible in one child with intensive avalglucosidase alfa treatment and immune tolerance induction, but it cannot predict typical outcomes for other infants. The mouse work helps researchers test treatments and measurements in a controlled setting, which can speed up learning, but animal results do not reliably predict human benefit. What becomes clearer this month is that early intensive approaches and better disease models are active areas of study, with the next step being larger and more representative human data. [12] [13]